Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
2025-01-15 16:24:31
Elevated Lead, Nickel, and Bismuth Levels in the Peritoneal Fluid of a Peritoneal Endometriosis Patient without Toxic Habits or Occupational Exposure following a Vegetarian DietA case study links elevated lead, nickel, and bismuth in peritoneal fluid with endometriosis, highlighting potential dietary and environmental exposures as contributors. Further research may identify these potentially toxic elements (TEs) as diagnostic biomarkers and therapeutic targets.
2025-01-14 13:43:44
Bradford Hill CriteriaThe Bradford Hill Criteria emphasized a holistic assessment of evidence to determine causality rather than requiring rigid experimental proof.
2025-01-03 16:59:33
Type 1 DiabetesMetal Homeostasis Copper dysregulation plays a definitive role in the pathogenesis of Type 1 Diabetes Mellitus (DM). Elevated copper levels increase the risk of developing DM by 15-fold per standard deviation, highlighting copper’s critical influence on oxidative stress and inflammatory pathways central to the disease. Studies show that DM patients exhibit higher copper levels and […]
2025-01-03 13:43:15
STOP: Indiscriminate Chlorhexidine Mouthwash Use Due to Breast Cancer RiskMicrobiome findings provide mechanistic insights into how chlorhexidine (HX) mouthwash might contribute to breast cancer and breast disease in a causal manner.
2025-01-01 12:49:39
The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health StudyThe study linked reduced oral microbiome diversity and altered microbial profiles to breast cancer and non-malignant breast disease, highlighting strong correlations between oral and fecal microbiomes in cases versus controls. Genera such as Porphyromonas showed significant inverse associations with breast cancer risk.
2025-01-01 11:45:39
Microbial Dysbiosis Is Associated with Human Breast CancerMicrobial dysbiosis, marked by reduced bacterial load and altered species composition, is linked to breast cancer progression. Enrichment of Methylobacterium radiotolerans in tumors and depletion of Sphingomonas yanoikuyae in normal tissue suggest diagnostic and therapeutic potential for microbiota-based interventions in breast cancer.
2025-01-01 11:33:38
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatmentGut microbiota influences early breast cancer prognosis and treatment side effects, with specific commensals correlating to outcomes. Chemotherapy alters microbiota, favoring beneficial species and improving immune modulation and neuroprotection.
2025-01-01 10:52:12
Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy womenThis study reveals distinct gut microbiota profiles in breast cancer and CIS patients, with reduced alpha diversity and functional shifts linked to inflammation. Major microbial associations, including enriched Bacteroides guilds, underscore potential microbiome-targeted interventions. Oral microbiota showed minimal differences, highlighting the gut’s critical role in breast cancer progression.
2025-01-01 10:39:45
Breast cancer in postmenopausal women is associated with an altered gut metagenomeThe study revealed altered gut microbiota in postmenopausal breast cancer patients, with enriched inflammation-associated species and depleted butyrate producers. Functional gene changes suggest links to systemic inflammation and metabolic imbalance, providing insights into microbiota’s role in cancer progression.
2025-01-01 10:20:09
Breast cancer but not the menopausal status is associated with small changes of the gut microbiotaThis study shows that breast cancer, rather than menopausal status, drives subtle gut microbiota changes. Dysbiosis in C patients included reduced Blautia obeum and Bifidobacterium. Functional impacts, such as downregulated AD pathways, suggest gut microbiota’s potential role in cancer progression.